ArticleBlood cancer journal2017
Germline mutations predisposing to diffuse large B-cell lymphoma.
Article in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Familial lymphoma and genetic predisposition: an updated review.BMC medical genomics · 2026Review
- Navigating primary and secondary immunodeficiency intersections: how to find IEI hidden within SID.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Review
- Multiple myeloma risk linked to DNA damage response genes.Journal of hematology & oncology · 2026Article
- Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy.Haematologica · 2025Review
- Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2025Review
- Germline mutations predispose a concurrent thymoma and diffuse large B-cell lymphoma.Annals of hematology · 2025Article
- Expression and Clinical Significance of CXCR5 and LAG-3 on Peripheral Blood CD8The Kaohsiung journal of medical sciences · 2025Article
- Article
- PD-L1Cold Spring Harbor molecular case studies · 2023Article
- Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer.Frontiers in oncology · 2023Article
- Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.Frontiers in immunology · 2023Article
- Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.Frontiers in immunology · 2022Article
- Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases.Frontiers in immunology · 2022Review
- T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.Frontiers in immunology · 2022Article
- The Mutation ofJournal of inflammation research · 2022Article
- Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas.International journal of molecular sciences · 2021Article
- Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series.Familial cancer · 2021Article
- Genomic profiling of CD20 negative diffuse large B cell lymphoma identifies targetable mutations: A case report.EJHaem · 2020Article
- Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma.Haematologica · 2020Article
- Germline Predisposition to Hematolymphoid Neoplasia.American journal of clinical pathology · 2019Review
Corrections and comments
- Erratum for
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.